Objective A systematic review and pooled analysis was carried out to estimate whether the increase in the quantity of cell-free fetal DNA (cffDNA) before the onset of preeclampsia (PE) can predict the disease using real-time polymerase chain reaction (PCR). Method A comprehensive literature search of the PubMed, Scopus, and Web of Knowledge databases was conducted to identify relevant studies that included evaluated cffDNA levels in pregnant women before the clinical onset of PE. A simulation model was generated to calculate the detection rate (DR) of cffDNA for PE, and a random variable was generated using the same number of cases and same statistical measurements of central tendency and dispersion as those reported in the papers considered for the analysis. Simulation of the receiver operating characteristic (ROC) curves was also carried out. Results Four studies (82 cases and 1315 controls) evaluated cffDNA in early-onset PE, with DRs of 18 and 68.8% at 11-13 and 17-28 weeks, respectively, at a false positive rate of 10%. Nine studies (including two considered for early-onset PE) encompassing 376 cases and 1270 controls were available for the evaluation of 'any PE'. At 11-14 weeks no significant DR was found, while at 15-28 weeks the DR was 37%. Conclusion CffDNA quantification is a marker for predicting the development of both early-onset PE and 'any PE'; however, it can probably only be used from the beginning of the second trimester, otherwise its predictive value is burdened with a DR that is too low or not significant. Due to the heterogeneity and difficulty in interpreting the published data, no conclusion regarding the statistical and clinical relevance, especially for screening 'any PE', can be made at present.
Introduction
Pre-eclampsia (PE) is a multisystem pregnancy-associated disorder that complicates 3-8% of pregnancies worldwide and is associated with significant maternal and perinatal morbidity and mortality [1] . PE is classified as early-or late-onset, depending on gestational age (before or after 34 weeks) of clinical onset [2] .
The etiopathogenesis of PE is still incompletely understood and is probably multifactorial. Development of the clinical signs of PE is thought to be the consequence of impaired trophoblastic invasion of the maternal spiral arteries, leading to placental hypoxia and the release of inflammatory cytokines, causing widespread vascular endothelial cell dysfunction [3, 4] .
There is currently no single reliable parameter for the prediction of PE and, therefore, multivariate screening methods based on ultrasound examination and the quantification of various serum and urinary biomarkers have recently been proposed [5, 6] .
Since Lo et al. [7] pioneered the demonstration and quantification of cell-free fetal DNA (cffDNA) in both maternal plasma and serum, the possibility of using cffDNA by means of real-time polymerase chain reaction (RT-PCR) as a molecular marker for feto-maternal diseases has been widely investigated. The source of the cffDNA is mainly the syncytiotrophoblast, the layer covering the villous tree that is in contact with the maternal blood in the intervillous space [8] . In particular, several studies have demonstrated that the maternal levels of cffDNA in pregnancies complicated by PE are higher than expected for normal pregnancies of peer gestational age [9] [10] [11] . The reasons for this increase are due to poor placentation leading to placental ischemia, with the release of aberrant amounts of necrotic and apoptotic fragments containing cffDNA into the maternal circulation. In pre-eclamptic women, there is not only an increased release of cffDNA into the maternal circulation but also a slower clearance rate from the maternal system [12] .
More interestingly, among women who develop PE, the levels of cffDNA are already elevated prior to the onset of clinical symptoms, as has recently been reported by Martin [11] . This is probably due to a pathological increase in placental apoptosis and necrosis, and reflects the beginning of placental insufficiency at an early gestational age.
However, whether cffDNA could be used as a predictive marker for PE is still controversial and, to date, the detection rate (DR) of this marker has not been properly assessed. In this pooled analysis, our aim was to calculate the DR of cffDNA for developing PE by analyzing all papers published in the literature to date that were considered eligible for data analysis (PubMed, Scopus and Web of Knowledge databases). Its relationship with gestational age, severity, and clinical onset was also evaluated using a simulation model.
Materials and Methods

Data Sources and Search Strategy
A protocol with defined objectives, criteria for study selection methods of quality analysis, and statistical methods was developed. Three independent researchers (AF, DB, and EC) conducted a search of the PubMed, Scopus, and Web of Knowledge databases through December 2015 using various combinations of the terms 'fetal DNA and preeclampsia', 'fetal DNA and preeclampsia screening' and 'screening for preeclampsia'. Potentially relevant articles were extracted, initially by title and abstract, and the full text of the articles were then retrieved for detailed review. The reference list of each article that met the inclusion criteria for this analysis was scanned and potentially eligible papers were retrieved for review. The search was not restricted to studies published in English; articles in languages other than English were dealt with using translators.
Those pregnancies that were normal at the time of enrollment, but which successively developed PE, were called 'cases', and those subjects who did not show any signs of PE throughout the pregnancy were called 'controls'. The definition of PE was taken from the International Society for the Study of Hypertension in Pregnancy, which requires the development of a diastolic blood pressure of C90 mmHg on at least two occasions, 4 h apart, after 20 weeks' gestation in previously normotensive women, and proteinuria of C300 mg in 24 h, or two readings of at least '??' on dipstick analysis of midstream or catheter urine specimens if no 24-h collection is available. The onset of PE at \34 weeks was considered 'earlyonset PE'.
Study Selection
Specific and prospectively defined inclusion criteria were established in order to identify the studies to be included in the systematic review. Papers were only considered eligible if they evaluated cffDNA in maternal plasma/serum/whole blood in women who developed PE later in pregnancy versus controls. The articles included in the systematic review had both prospective (cohort or case-control) and retrospective study designs, and reported the measurements of cffDNA at any trimester of pregnancy expressed in central tendency (mean or median) and dispersion (standard deviation [SD], minimum-maximum, 5-95 percentile, 10-90 percentile, interquartile range [IQR], or standard error of the mean [SEM]). The search was limited to studies on humans and peer-reviewed literature. Papers not meeting the criteria of the present systematic review were excluded from the analysis but were eventually cited in the text for their clinical relevance.
Overall, 560 primary articles that met the selection criteria were identified by searching the PubMed, Scopus and Web of Knowledge databases. Of these, 18 were retrieved as potentially eligible primary studies for detailed evaluation and inclusion in the pooled analysis. With regard to screening, the vast majority of the studies (399) dealt with the use of different combinations of biochemical, urinary, and/or ultrasound markers, but did not produce any proper screening model. Seventy-three used specific mathematical algorithms for a biochemical/ultrasound/ history-based screening model at the first trimester, and 53 at the second trimester. Seventeen papers evaluated circulating and/or trophoblastic messenger RNA (mRNA) species to predict PE. Of the remaining 18 papers, 7 were excluded for various reasons, including violation of the statistical assumptions and the use of heterogeneous cffDNA dose strategies, not including RT-PCR. Eleven articles were therefore included in the present analysis (see Fig. 1 for the study selection process). All papers included in our analysis evaluated the cffDNA, measured by means of RT-PCR in patients who subsequently developed PE. One article [13] considered early PE, three [14] [15] [16] considered both early and late PE (but, with the exception of Jakobsen's paper [16] , only the results relative to early PE were included), and seven [17] [18] [19] [20] [21] [22] [23] did not differentiate the type of PE and were therefore classified as 'any PE'. The studies by Sifakis et al. [14] and Levine et al. [15] were also included in the 'any PE' arm of the analysis.
For the early PE analysis, the studies were divided into two groups: the 11-to 13-week window [14] and the 17-to 28-week [13, 15, 16] window. However, the gestational age interval for the 'any PE' analysis was 11-14 weeks [14, 17] and 15-28 weeks [15, [17] [18] [19] [20] [21] [22] [23] .
Statistical Analysis
Heterogeneity across the studies was assessed using the I 2 value and the Chi-square-based Q test. A p value [0.10 for the Q test or an I 2 value \50% revealed no obvious heterogeneity across the studies, allowing the use of a fixed-effects model (the Mantel-Haenszel method); otherwise, a random-effects model was selected (the DerSimonian and Laird method).
In this study, a simulation model was generated to calculate the DR of cffDNA for PE, stratified according to type (early-onset or 'any PE') and trimester. A random variable was generated using a routine command implemented in SPSS (Statistical Software for Social Science), called RV.RANDOM (X;Y), having the same number of cases and same values of the measurement of central tendency (X) and dispersion (Y) as those reported in the papers considered for the analysis. The IQR and SEM, where reported, were converted into SD using the following formulas: SD = IQR/1.35, or SD = SEM 9 ffiffi ffi n p (where n is the number of cases), respectively. In studies only reporting the receiver operating characteristic (ROC) curve, the DR, false positive rate (FPR), and number of cases at each cut-off point were calculated by visual inspection. Finally, in order to allow a more proper homogenization of the data, the simulated values of each study were divided by the respective mean value of the controls in order to obtain a standardized mean value of 1.00 ± SD in the control population. This was done to reduce the interstudy variability of the cffDNA as much as possible. A bootstrap procedure was also used to validate the robustness of the results. Comparisons were carried out using the Student's t-test or Mann-Whitney U test. After standardization, the data were pooled to generate the univariable DR using ROC curve analysis. Finally, a power analysis (at a type I error of 5%) was carried out for each study and for the cumulative data set, obtained by pooling all the cases. IBM SPSS statistics 22 (IBM Corporation, Armonk, NY, USA) and a comprehensive meta-analysis were used for the statistical analyses.
In order to detect possible confounders regarding the cffDNA values due to the clinical variables, including maternal age, body mass index (BMI), parity, familial history of PE, and a history of PE, a weighted correlation using the ratio between cffDNA in cases and controls (as a Y-dependent variable), and the differences in the variables of interest between cases and controls (as X-independent variables), was carried out. In particular, by using this strategy, each dot of the line of regression represents a single study, and the independent variable was priori ranked in increasing order.
Results
Sources of variability among the various studies are represented by the different populations enrolled, which differed among the studies in terms of parity, BMI, familial history of hypertension, and rate of medical complications, as reported in Table 1 .
As shown, the classical predictors of PE are distributed very differently among the various studies, and also between the cases and controls belonging to the same study. Once again, across the studies, increasing differences in the BMI between cases and controls, at least for the 'any PE' group at the second trimester, was inversely correlated with the cffDNA values (Fig. 2) 
Studies on Early/Severe Pre-Eclampsia (PE)
A relatively small number of eligible cases (82) were found in the medical literature. Two of four studies considered PE to be early when the clinical onset was before 34 weeks, and one [15] considered PE to be early when the clinical onset was before 37 weeks. Jakobsen et al. [16] considered severe PE, but it is reasonable that all (or at least the vast majority) of those cases were early PE since the gestational age at delivery was approximately 36 weeks. The DR of cffDNA for early PE was reported in only two papers [15, 16] ; however, in another two papers [14, 15] , it was possible to indirectly calculate the DR using a simulation model. The total number of early PE cases and controls included in the analysis was 11 and 176, respectively, in the 11-to 13-week group, and 71 and 1139, respectively, in the 17-to 28-week group. Table 2 reports the estimated measurements of central tendency and dispersion in log10 scale.
The degree of heterogeneity yielded a p value [0.10 for the Q test and an I 2 of 67%. Using a random model, the estimated multiples of the mean ± SD were 1.00 ± 0.18 and 1.14 ± 0.09 at 11-13 weeks, and 1.00 ± 0.25 and 1.66 ± 0.24 at 17-28 weeks, respectively. Unfortunately, in their analysis, Jakobsen et al. [16] only provided the cffDNA values of the overall population, without stratifying the medians or means according to PE cases and controls. Therefore, their data were not added to the multiple of mean calculation at 17-28 weeks; however, it was possible to add the latter to the overall DR calculation by simulating the ROC curve reported in the paper.
The DRs are reported in Table 3 . As shown, for early PE at 11-13 weeks' gestation, a low but significant 18% DR was validated, simulating the data in a single paper by Sifakis et al. [14] . At 17-28 weeks, higher (and quite similar) DRs were reported by Yu et al. and Levine et al. [13, 15] followed by Jakobsen et al. [16] . The cumulative DR was 68.8% (Fig. 3) .
The differences found in the four studies were surely due to the heterogeneous gestational ages at the time of enrollment. Another reason can be found in the population enrolled, which differs among the studies in terms of parity, BMI, familial history of hypertension, and rate of medical complications (Table 1) . For example, in the study by Sifakis et al. [14] the rate of nulliparity is 72.2% for PE cases versus 50% for controls, a difference of 22.2%. However, in the study by Yu et al. [13] even if the rate of nulliparity in PE cases was quite similar (80%) to that in the study by Sifakis et al., in the controls it was as high as 88.5%. Other incongruences can be found for both BMI and maternal age, as reported in Table 1 . It is evident that these covariates, as well as others that are probably unknown or not reported, affect the cffDNA values, especially in the first trimester when the quantity of cffDNA is quite low, and possible differences between patients who will or will not develop PE are less marked. Finally, as shown in Fig. 2 , a regression line showing the differences in BMI versus the cffDNA (expressed as a ratio between cases and controls) revealed that as the differences in BMI increase, the cffDNA decreases. 
Studies Regarding 'Any PE'
Nine studies (the study by Kim et al. [17] was included twice for 11-14 and 15-28 weeks evaluations) met the inclusion criteria. The main reasons for exclusion were the impossibility of properly simulating the data sets that were burdened with a consistent presence of outliers [24, 25] and/or missing information regarding the cffDNA central tendency and dispersion measurements of the affected population [26, 27] . Two papers [28, 29] used a fetal fraction assessment derived from wholegenome random sequencing and digital analysis of selected regions (DANSR   TM   ) instead of RT-PCR. It was only possible to include the DR from a paper by Cotter et al. [18] since it was clearly reported along with the FPR and the relative cffDNA cut-off points; however, the measurements of dispersion were not reported. Two papers considered for early PE analysis [14, 15] were also used for the 'any PE' analysis since data on both types of PE were reported. The total number of 'any PE' cases and controls included in the analysis was 48 and 212, respectively, in the 11-to 14-week group, and 332 and 1084, respectively, in the 15-to 28-week group. It should be noted that the data of Kim et al. [17] were counted twice and therefore the total number of patients enrolled was 376 cases and 1260 controls (36 controls and 4 cases had to be excluded). Table 4 reports the estimated measurement of central tendency and dispersion in log10 scale.
The degree of heterogeneity yielded a p value[0.10 for the Q test and an I 2 of 80%. Using a random model, the estimated multiples of mean ± SD were 1.00 ± 0.24 and 1.11 ± 0.26 at 11-14 weeks, and 1.00 ± 0.33 and 1.21 ± 0.83 at 15-28 weeks, respectively. Two papers [14, 17] were available for the evaluation of any PE (11-14 weeks). However, as shown in Table 5 , the ROC curve did not reach statistical power and was therefore excluded from further evaluation. Based on these data, it seems that, at present, the 'any PE' group cannot be properly screened in the first trimester. In fact, the DR is too low to be clinically significant. For the 15-to 28-week window, eight studies were available but, unfortunately, the DRs Fig. 2 Regression line showing an inverse relationship between the BMI (expressed as the difference between cases and controls) and cffDNA (expressed as a ratio between cases and controls) in the 'any PE in the second trimester' subgroup. Each dot represents a single study. BMI body mass index, cffDNA cell-free fetal DNA, PE preeclampsia of the individual papers ranged from 15 to 100%, and two papers [20, 22] did not reach sufficient statistical power (Table 5 ). Such discordance is probably due to the different populations enrolled, the wide window in gestational age, and the very wide data dispersion. However, the simulation model yielded a DR of 37% (Table 5 ; Fig. 4 ).
Discussion
Both total and fetal DNA have been proposed as potential markers for PE. A poorly perfused placenta may release circulating factors into the maternal circulation, damaging the maternal vascular endothelial cells [26] and leading to multisystem dysfunction [27] , and thus explaining the increase in circulating total DNA (quantified by using bglobin).
In this systematic review, the possible role of cffDNA for early and 'any PE' screening was evaluated using a simulation model that included a large proportion of the data reported in the literature to date. To our knowledge, this is the first review that attempts to calculate the DR for each study included and, more importantly, an overall DR calculated by pooling all the cases available (Figs. 3, 4) .
Increased levels of cffDNA in early pregnancy have been associated with an increased risk of developing PE and fetal growth restriction in many papers [18, 28] ; however, this association has not been found by others. For example, Nicolaide's group could not replicate these results in two retrospective analyses of prospectively collected first-trimester serum samples [29, 30] .
In the second trimester of pregnancy, the majority of studies [22, 25] did not find a correlation between increased levels of cffDNA and adverse pregnancy outcome, while others found a correlation not only between increased levels of cffDNA at 25 weeks and developing PE but also, interestingly, between lower levels of cffDNA and adverse pregnancy outcome [16] .
However, what emerges from the present review is that, even if much speculation has been made regarding the use of cffDNA as a molecular marker for PE prediction, the data are far from being conclusive. In fact, surprisingly, the 'posterior risk' of a specific cffDNA cut-off value for PE has never been calculated, and cffDNA has never been integrated into a multivariable model, as has, however, been done for biochemical markers [5, 21] . A preliminary non-parametric analysis of the DR of cffDNA to predict PE in low risk non-symptomatic women has previously been carried out [20] ; however, a proper posterior risk of the DR detection rate, FPR false positive rate, CI confidence interval, AUC area under the curve a The original DR was 90% and was calculated at 15% FPR, with a cut-off of 2.62. The estimated DR was 90% at 15% FPR, with a cut-off of 2.64. For comparative purposes, the FPR was set at 10% b The original DR was 40% and was calculated at 5% FPR, with a cut-off of 173 gen/mL. The estimated DR was 40% at 4.1% FPR, with a cutoff of 173 gen/mL or a 1.95 multiple of the mean. For comparative purposes, the FPR was set at 10% c The Jakobsen data were not included in the multiple of mean calculation but were, however, available for the DR calculation Fig. 3 Receiver operating characteristic curve analysis. Detection rate of cell-free fetal DNA for early pre-eclampsia at 17-28 weeks' gestation disease using cffDNA alone or in combination with other markers could not be calculated in that study. The differences in the populations examined have previously been mentioned. Parity, BMI, ethnicity, familial history of hypertension, and other covariates (which we could not include in this pooled analysis) play an important role in determining the DR of cffDNA, and may consistently modify cffDNA performance. For example, Poon et al. [30] reported a correlation of cffDNA with race, smoking status and BMI. Finally, the DR is, of course, greatly influenced by gestational age; a useful value for screening purposes can only be obtained beginning from the second trimester. Again, a very different rate of PE was observed in each series and, for this reason, the majority of results from case-control studies have probably not been confirmed by retrospective cohort studies.
There is also a difference in the method of cffDNA analysis. The majority of studies published used a chromosome Y gene marker to quantify fetal cffDNA, or RhDspecific sequences, thus limiting the analysis to male or Rh-positive fetuses. In particular, Cotter et al. observed increased levels of the fetal RhD gene in mothers who subsequently developed PE, with a direct correlation between the quantity of fetal DNA and the severity of the PE [23] . Recently, RASSF1A [17, 24, 31] and unmethylated-maspin DNA [32] present in maternal blood have also been proposed as molecular markers of PE. There is no evidence that one cffDNA marker is better than another, but it can be speculated that some concomitant genetic diseases can alter the quantity of cffDNA. For example, the maspin gene is mapped to chromosome 18q21.33, and it has been reported to be higher in trisomy 18 cases [33] . Once again, the Y chromosome marker can be affected by the presence of a sex chromosome aneuploidy (SCA), including Y disomy (Jacob's syndrome). Finally, the RhD marker can only be used in RhD-negative women, and the amplification could be affected by the simultaneous presence of the maternal w pseudogene [34] . Our group acknowledges the limitations of this analysis which are, however, unavoidable considering the heterogeneous and fragmentary data on this topic. In the various studies, the percentages of early/late-onset PE, as well as mild/intermediate/severe PE (which are also reasonably inhomogeneous in the various studies) are not reported. This is obviously an important source of bias because, if the types of PE are not divided into distinct categories, we do not know the single contribution to cffDNA aberration, and are less likely to obtain results that are both comparable and reliable.
It must also be noted that many studies do not report any follow-up of the PE cases, neither therapeutic strategies for monitoring the PE evolution, nor the eventual resorting to a cesarean section to prevent the risk of other clinical complications.
Notwithstanding the limitations of this pooled analysis, the strength of this study is the rigorous selection process. Even if other papers have reported the cffDNA levels in asymptomatic women who developed PE, some of them were not included in this pooled analysis since it was not possible to recalculate the data distribution due to violation of the statistical assumptions. The main reason for this failure was too wide a dispersion of cffDNA distribution which, in some cases, also included the value 0 when defining the lower boundary point.
Conclusions
A reliable estimation of DRs and the relative predictive value of cffDNA for PE screening purposes is still far from a clinical application. Only a few studies have been reported in the literature and they are not prospective, are very heterogeneous, and are burdened with very wide and skewed data dispersion, which makes it impossible to understand the real performance of this marker. However, DR detection rate, FPR false positive rate, cffDNA cell-free fetal DNA, CI confidence interval, AUC area under the curve Fig. 4 Receiver operating characteristic curve analysis. Detection rate of cell-free fetal DNA for any pre-eclampsia at 15-28 weeks' gestation given the statistical power reached by almost all of the studies herein presented, it can be speculated that, starting from the second trimester, cffDNA could potentially be used as a predictive marker for early PE. Moreoever, given the late gestational age at the time of screening, the possible impact for PE prevention remains questionable. There is no clear evidence that cffDNA is useful in predicting late PE because, first, only a few studies have clearly stated that late PE cases were included and, second, when considering 'any PE', the papers did not usually report the percentages of late and early PE that were included. Unfortunately, in line with Poon et al. [30] and Sifakis et al. [9] we suggest at this time for non-invasive prenatal testing (NIPT) for fetal genetic screening purposes, the cffDNA fractions (reported by several companies that offer NIPT) does not seem to be useful for PE screening purposes. Some other screening methods, based on biochemical markers, such as the SFlt-1/PlGF ratio, have demonstrated a better performance for PE screening at a lower cost and could be more feasible in clinical practice than cffDNA [35] .
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